Innovating Novel Combination Therapies & Maximising Preclinical & Clinical Development to Improve Glioblastoma Targeting & Increase Investment Opportunities to Ultimately Bring Efficacious Therapies to Patients in Need
Glioblastoma has long remained one of the most aggressive and devastating cancers, leaving patients and families with limited options and an urgent need for progress. In recent years, however, the treatment landscape has begun to shift, growing significantly as science‑driven approaches and novel therapies gained momentum. Merck’s landmark acquisition of Modifi Bio proved to be more than a business milestone—it became a powerful signal of renewed hope in a field that had long faced barriers to investment and breakthroughs.
As we moved into 2026, sustaining this momentum became not only important but critical for the patients who could not wait.
The 7th Glioblastoma Drug Development Summit served as a pivotal moment to accelerate innovation and bring life‑changing therapies closer to those who need them most.
Over three transformative days - featuring six deep‑dive workshops and more than 90 leading experts from biotech, pharma, and investment - we united around one shared mission: to change the future for glioblastoma patients.
Together, we explored:
- Innovating combination strategies to overcome resistance and improve patient outcomes
- Building robust preclinical and clinical frameworks to shorten the path from lab to bedside
- Mobilizing investment and collaboration to deliver promising therapies faster
- Harnessing AI’s power to unlock new insights and accelerate research
Leading organizations, including Laminar Pharma, Medicenna, Merck, AstraZeneca, CNS Pharmaceuticals, Imvax, Tactical Therapeutics, and many others came together to turn scientific ambition into tangible patient impact.
Every breakthrough achieved represented more than scientific progress; it signified hope for patients, families, and communities affected by glioblastoma. Together, we helped move the standard of care forward and delivered meaningful advances where they were most urgently needed.
Companies That Attended Include
The diverse content that covered everything from funding GBM trials to new technologies/approaches to early clinical solutions. The round tables were a good way to promote discussion.
Chief Business Officer, Global Coalition for Adaptive Research
I was extremely pleased with the way the entire summit was organized. Everything from the line up of the speakers to the networking opportunities was very well planned and executed.
VP, Research & Development, Diakonos Oncology
The summit covered diverse important topics in GBM field, ranging from more basic to clinical and investment. Great opportunities for discussion on key open topics to understand perspective from leaders in their area of focus.
CEO, Medicenna Therapeutics
Explore the Full Event Guide
- 90+ industry attendees
- 25+ World Class Speaker
- 6 deep-dive workshops, covering end-to-end drug development
- 8+ Hours on Networking
- The world’s only industry-led forum focussed on Glioblastoma drug development
Official 2026 Partners
Explore Related Events
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.